Skip to content

The efficacy of flexor tenotomy on the prevention of recurrent diabetic foot ulcers: a randomized controlled trial

The efficacy of flexor tenotomy on the prevention of recurrent diabetic foot ulcers: a randomized controlled trial - Flexor tenotomy and ulcer recurrence

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON50013
Enrollment
66
Registered
2021-10-07
Start date
2022-03-15
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic sores Diabetic ulcers

Interventions

A flexor tenotomy of toes with a claw or hammer toe deformity (intervention) versus control group (standard of care including orthosis and shoe offloading).

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • A minimum age of 18 years • Sufficient understanding of Dutch/English language • Capable of filling out informed consent • Peripheral polyneuropathy • Diabetes mellitus type 1 or 2 • Claw and/or hammer toe deformity • A documented history of diabetic ulcers underneath the tip of the toe

Exclusion criteria

Exclusion criteria: • No written informed consent • Not meeting the inclusion criteria • Open ulcers on the toes • Previous participation in the study • Pregnant women • Concomitant participation in a study in which the patient is exposed to X-rays

Design outcomes

Primary

MeasureTime frame
Ulcer recurrence of the toe, adjacent toe or metatarsal heads after one year of follow-up.

Secondary

MeasureTime frame
Changes in distal interphalangeal joint, proximal interphalangeal joint and metatarsophalangeal joint angles before and after flexor tenotomy in a weight-bearing and non-weight-bearing position, barefoot pressure pattern before and after flexor tenotomy, quality of life at inclusion and follow-up and cost-effectiveness.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)